Karo Pharma’s rights issue fully subscribed
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.The result of Karo Pharma Aktiebolag’s (“Karo Pharma”) rights issue of approximately SEK 2.5 billion (the “Rights Issue”) shows that 47,954,417